Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Soligenix Inc (SNGX)

Soligenix Inc (SNGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,232
  • Shares Outstanding, K 987
  • Annual Sales, $ 840 K
  • Annual Income, $ -6,140 K
  • 60-Month Beta 1.88
  • Price/Sales 2.67
  • Price/Cash Flow N/A
  • Price/Book 2.18
Trade SNGX with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +13.00%
on 07/02/24
5.47 -58.67%
on 06/05/24
-2.81 (-55.44%)
since 06/03/24
3-Month
2.00 +13.00%
on 07/02/24
14.92 -84.85%
on 04/15/24
-5.50 (-70.89%)
since 04/03/24
52-Week
2.00 +13.00%
on 07/02/24
32.00 -92.94%
on 11/30/23
-9.10 (-80.11%)
since 07/03/23

Most Recent Stories

More News
Soligenix to Present at The ThinkEquity Conference

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

SNGX : 2.26 (-0.44%)
Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

SNGX : 2.26 (-0.44%)
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

SNGX : 2.26 (-0.44%)
Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results

/PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

SNGX : 2.26 (-0.44%)
HyBryteâ„¢ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

SNGX : 2.26 (-0.44%)
Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

SNGX : 2.26 (-0.44%)
Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

SNGX : 2.26 (-0.44%)
Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

SNGX : 2.26 (-0.44%)
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryteâ„¢ in the Treatment of Cutaneous T-Cell Lymphoma

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

SNGX : 2.26 (-0.44%)
Soligenix Announces Closing of $8.5 Million Public Offering

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

SNGX : 2.26 (-0.44%)

Business Summary

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable...

See More

Key Turning Points

3rd Resistance Point 2.39
2nd Resistance Point 2.37
1st Resistance Point 2.31
Last Price 2.26
1st Support Level 2.23
2nd Support Level 2.21
3rd Support Level 2.15

See More

52-Week High 32.00
Fibonacci 61.8% 20.54
Fibonacci 50% 17.00
Fibonacci 38.2% 13.46
Last Price 2.26
52-Week Low 2.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar